Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine

Use of PELC/CpG Adjuvant for Intranasal Immunization with Recombinant Hemagglutinin to Develop H7N9 Mucosal Vaccine

Human infections with H7N9 avian influenza A virus can result in severe diseases with high mortality. Developing an effective vaccine is urgently needed to prevent its pandemic potential. Vaccine delivery routes via mucosal surfaces are known to elicit mucosal immune responses such as secretory IgA...

Full description

Bibliographic Details
Main Authors: Ting-Hsuan Chen, Chung-Chu Chen, Ming-Hsi Huang, Chung-Hsiung Huang, Jia-Tsrong Jan, Suh-Chin Wu
Format: Article
Language:English
Published: MDPI AG 2020-05-01
Series:Vaccines
Subjects:
H7N9
intranasal
adjuvant
mucosal vaccine
Online Access:https://www.mdpi.com/2076-393X/8/2/240

Similar Items

Similar Items